Macquarie Group LTD Zentalis Pharmaceuticals, Inc. Transaction History
Macquarie Group LTD
- $85.1 Billion
- Q2 2024
Shares
3 transactions
Others Institutions Holding ZNTL
# of Institutions
148Shares Held
69.8MCall Options Held
61.8KPut Options Held
6.6K-
Matrix Capital Management Company, LP Waltham, MA14MShares$52.3 Million0.43% of portfolio
-
Eventide Asset Management, LLC Boston, MA8.55MShares$32.1 Million0.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.65MShares$21.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$18.1 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.5MShares$16.9 Million0.0% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $214M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...